FDA Approves Mylan’s Yasmin Copies

Following approval from the US Food and Drug Administration (FDA), Netherlands-domiciled Mylan has launched generic copies of Bayer's drospirenone and ethinyl estradiol-based contraceptive tablets sold under the Yasmin brand name.

It is Mylan’s thirteenth launch of a generic oral contraceptive on the US market.

The application made by Mylan’s partner Famy Care was greenlighted under the FDA’s Abbreviated New Drug Application (ANDA) scheme.

US brand sales of the 3 mg/0.03 mg tablets totaled about $137.6 million for the 12 months ending June 30, 2015, according to figures released by IMS Health.

Currently, Mylan has 266 ANDAs pending FDA approval, representing $99.5 billion in annual brand sales. Some 50 of the pending ANDAs are said to be potential first-to-file opportunities, with a brand sales value of $33.4 billion.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.